Nektar Therapeutics (NKTR) News Today $25.84 +0.08 (+0.31%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NKTR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Nektar Therapeutics launches proposed public offeringJune 30 at 6:42 PM | msn.comNektar Therapeutics stock falls after announcing public offeringJune 30 at 6:42 PM | in.investing.comNektar Therapeutics Announces Proposed Public OfferingJune 30 at 4:02 PM | prnewswire.comBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsWith major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?June 30 at 2:21 PM | marketbeat.comWhat is HC Wainwright's Estimate for NKTR Q2 Earnings?June 29 at 2:19 AM | americanbankingnews.comNektar Jumps 157% on Drug Trial Data-Can It Go Even Higher?June 28 at 12:46 PM | msn.comNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.June 28 at 8:15 AM | marketbeat.comNektar Therapeutics Regains Nasdaq Compliance by June 2025June 27, 2025 | tipranks.comNektar Therapeutics Scores Big Phase 2b Win With RezpegJune 27, 2025 | seekingalpha.comHC Wainwright Analysts Boost Earnings Estimates for NKTRJune 27, 2025 | marketbeat.comResearch Analysts Set Expectations for NKTR Q1 EarningsJune 26, 2025 | marketbeat.comRhumbline Advisers Purchases 41,948 Shares of Nektar Therapeutics (NASDAQ:NKTR)June 26, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Expected to Rise, HC Wainwright Analyst SaysJune 26, 2025 | americanbankingnews.comWhy Nektar Therapeutics Stock Was Red-Hot TodayJune 25, 2025 | fool.comNektar Therapeutics (NKTR) Jumps as Eczema Trial SucceedsJune 25, 2025 | gurufocus.comNektar Therapeutics surge continues as stock up another 25%June 25, 2025 | seekingalpha.comWhy Is Nektar Therapeutics Stock Trading Higher On Wednesday?June 25, 2025 | benzinga.comNektar Therapeutics stock soars after atopic dermatitis drug hits key targetsJune 25, 2025 | ca.investing.comNektar Therapeutics Stock Doubles After Promising Eczema Drug Trial ResultsJune 24, 2025 | msn.comNektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising FurtherJune 24, 2025 | msn.comBTIG Research Forecasts Strong Price Appreciation for Nektar Therapeutics (NASDAQ:NKTR) StockJune 24, 2025 | marketbeat.comNektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?June 24, 2025 | forbes.comNektar Therapeutics (NKTR) Sees Dramatic Price Target Increase | NKTR Stock NewsJune 24, 2025 | gurufocus.comHC Wainwright Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock PriceJune 24, 2025 | marketbeat.comNektar Therapeutics Shares Double On Promising Eczema Drug DataJune 24, 2025 | benzinga.comNektar Therapeutics Announces Positive Phase 2b Trial ResultsJune 24, 2025 | tipranks.comNektar Therapeutics' experimental eczema drug meets main goals of mid-stage trialJune 24, 2025 | reuters.comREZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic DermatitisJune 24, 2025 | prnewswire.comWhy Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving PremarketJune 24, 2025 | benzinga.comNektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours AwayJune 24, 2025 | msn.comResearch Analysts Set Expectations for NKTR Q2 EarningsJune 24, 2025 | americanbankingnews.comStocks to Watch: Nektar Therapeutics, AlsetJune 23, 2025 | marketwatch.comNektar Stock Soars Ahead of Dermatitis Drug Study DataJune 23, 2025 | marketwatch.comNektar Therapeutics stock soars on upcoming atopic dermatitis dataJune 23, 2025 | investing.comNektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025June 23, 2025 | prnewswire.comZacks Research Issues Optimistic Forecast for NKTR EarningsJune 23, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Buy" by AnalystsJune 13, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Short Interest UpdateJune 11, 2025 | marketbeat.comNektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POCJune 11, 2025 | seekingalpha.comNektar Therapeutics (NASDAQ:NKTR) Shares Down 7.6% - Here's WhyJune 11, 2025 | marketbeat.comAMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and ProvenanceJune 10, 2025 | globenewswire.comNektar Therapeutics (NASDAQ:NKTR) Trading 12.1% Higher - What's Next?June 10, 2025 | marketbeat.comSquarepoint Ops LLC Purchases Shares of 139,758 Nektar Therapeutics (NASDAQ:NKTR)June 10, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sees Strong Trading Volume - Here's What HappenedJune 9, 2025 | marketbeat.comShort Interest in Nektar Therapeutics (NASDAQ:NKTR) Increases By 19.4%June 5, 2025 | marketbeat.comNektar Therapeutics Approves Reverse Stock SplitJune 4, 2025 | tipranks.comMackenzie Financial Corp Buys 417,651 Shares of Nektar Therapeutics (NASDAQ:NKTR)June 4, 2025 | marketbeat.comMillennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR)May 31, 2025 | marketbeat.comNatural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 29, 2025 | theglobeandmail.comNektar Therapeutics Elects New Board, Approves Key ProposalsMay 28, 2025 | tipranks.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.910.90▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼405▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
